|Print Page | Close Window|
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.
Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, SUBSYS®, a sublingual Fentanyl spray for breakthrough cancer pain launched in March of 2012, and SYNDROS®, the first and only FDA-approved liquid dronabinol for loss of appetite in AIDS patients and nausea and vomiting caused by anti-cancer medicine (chemotherapy). Please see full prescribing information for SUBSYS® and SYNDROS® including the boxed warning.
Our product pipeline is aimed at addressing conditions with unmet medical needs, such as refractory pediatric epilepsy (including childhood absence epilepsy and infantile spasms), the genetic disorder Prader-Willi syndrome, anorexia-associated weight loss in cancer patients, agitation in Alzheimer's disease, migraine, anaphylaxis (severe allergic reaction), acute pain, opioid dependence and reversal of opioid-induced respiratory depression.
Jun 18 2018
INSYS Therapeutics Provides an Update on Its Ongoing Transformation
PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reiterated its ongoing efforts to fundamentally transfo...
Jun 14 2018
Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
PHOENIX, June 14, 2018 (GLOBE NEWSWIRE) -- Allergy sufferers who experience anaphylaxis—an acute, life-threatening allergic reaction requiring urgent treatment—may soon have a new delivery option for receiving a timely dose of epinephrine to avoid a potentiall...
see all news
Jun 04 2018
INSYS Therapeutics to Present at Jefferies Global Healthcare Conference
PHOENIX, June 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, president and chief exec...